Baxdrostat: A Next-Generation Aldosterone Synthase Inhibitor Offering New Hope in Resistant Hypertension
Biomolecules · 2025
DOI: 10.3390/biom15101439 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Biomolecules, 2025. Verfasst von Ewelina Młynarska und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrocardiology, Medical University of Lodz, Ul. Zeromskiego 113, 90-549 Lodz, Poland. Hauptthemen laut MEDLINE: Hypertension, Cytochrome P-450 CYP11B2, Antihypertensive Agents, Enzyme Inhibitors. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 118 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Hypertension is a leading global cause of cardiovascular disease and mortality, with resistant hypertension (RH) posing treatment challenges. Aldosterone synthase inhibitors (ASIs) are a novel drug class that reduce blood pressure by lowering aldosterone levels. Baxdrostat is a selective ASI that inhibits the CYP11B2 enzyme, responsible for aldosterone synthesis, without affecting cortisol production. This selectivity minimizes hormonal side effects. Clinical trials have shown that baxdrostat reduces plasma aldosterone in a dose-dependent manner while preserving cortisol levels. In the Phase 2 BrigHTN trial, baxdrostat significantly lowered systolic and diastolic blood pressure in patients with RH, with the 2 mg dose showing the most consistent efficacy. However, in the HALO trial, similar blood pressure reductions were observed in the placebo group, possibly due to improved adherence to background antihypertensive therapy. Baxdrostat has demonstrated a favorable safety profile, with mostly mild adverse effects and no significant impact on kidney function. It is considered safe for use with other medications, including metformin. Ongoing trials are investigating its potential in patients with chronic kidney disease (CKD) and primary hyperaldosteronism (PA). Baxdrostat represents a promising therapeutic option for aldosterone-driven hypertension, especially in patients unresponsive to standard treatments.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nephrocardiology, Medical University of Lodz, Ul. Zeromskiego 113, 90-549 Lodz, Poland.
- Department of Nephrology, Hypertension and Family Medicine, Medical University of Lodz, Ul. Zeromskiego 113, 90-549 Lodz, Poland.
ORCID-Profile: Ewelina Młynarska, Natasza Dzieża, Magdalena Stabrawa
Zitieren
APA
Młynarska, E., Czarnik, W., Dzieża, N., Jędraszak, W., Majchrowicz, G., Prusinowski, F., Stabrawa, M., Rysz, J., & Franczyk, B. (2025). Baxdrostat: A Next-Generation Aldosterone Synthase Inhibitor Offering New Hope in Resistant Hypertension. Biomolecules. https://doi.org/10.3390/biom15101439
Vancouver
Młynarska E, Czarnik W, Dzieża N, Jędraszak W, Majchrowicz G, Prusinowski F, et al. Baxdrostat: A Next-Generation Aldosterone Synthase Inhibitor Offering New Hope in Resistant Hypertension. Biomolecules. 2025. doi:10.3390/biom15101439
BibTeX
@article{Mynarska2025,
author = {Młynarska, Ewelina and Czarnik, Witold and Dzieża, Natasza and Jędraszak, Weronika and Majchrowicz, Gabriela and Prusinowski, Filip and Stabrawa, Magdalena and Rysz, Jacek and Franczyk, Beata},
title = {Baxdrostat: A Next-Generation Aldosterone Synthase Inhibitor Offering New Hope in Resistant Hypertension},
journal = {Biomolecules},
year = {2025},
doi = {10.3390/biom15101439}
}
EUVIMED